Ovid Therapeutics
New York
About Ovid Therapeutics
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $332.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:OVID
- Website: ovidrx.com
- Phone: (212) 776-4381
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/ovid-therapeutics-59248 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.